Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Aloxi (capsule) | Palonosetron | Chemotherapy-induced nausea and vomiting | Withdrawn | |||
| Aloxi (injection) | Palonosetron hydrochloride | Chemotherapy-induced nausea and vomiting | Do not list at the submitted price | Complete | ||
| Aloxi (capsule) | Palonosetron hydrochloride | Chemotherapy-induced nausea and vomiting | Do not list | Complete | ||
| Dysport Therapeutic | abobotulinumtoxinA | Cervical dystonia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xeomin | Clostridium botulinum neurotoxin type A, free from complexing proteins | Cervical Dystonia | List in a similar manner | Complete | ||
| Avastin | Bevacizumab | Cervical Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xermelo | telotristat | carcinoid syndrome | Do not reimburse | Complete | ||
| VFEND | Voriconazole | Candidemia | List with clinical criteria and/or conditions | Complete | ||
| Nexavar | Sorafenib tablets | Cancer, Renal cell carcinoma | Do not list | Complete | ||
| Trelstar | Triptorelin pamoate | Cancer, prostate | List in a similar manner to other drugs in class | Complete |
Last Updated : May 11, 2024